Shares of CureVac (NASDAQ:CVAC - Get Free Report) saw strong trading volume on Friday . 1,049,276 shares were traded during trading, an increase of 29% from the previous session's volume of 812,320 shares.The stock last traded at $3.00 and had previously closed at $2.80.
Wall Street Analysts Forecast Growth
Separately, JMP Securities restated a "market outperform" rating and issued a $16.00 price objective on shares of CureVac in a report on Friday, February 14th.
Check Out Our Latest Stock Report on CureVac
CureVac Trading Down 1.8 %
The company has a market capitalization of $608.95 million, a PE ratio of 4.95 and a beta of 2.53. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. The company's fifty day moving average is $3.35 and its 200-day moving average is $3.19.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Integrated Wealth Concepts LLC bought a new stake in CureVac during the third quarter valued at about $35,000. Jane Street Group LLC lifted its position in shares of CureVac by 239.0% during the third quarter. Jane Street Group LLC now owns 79,247 shares of the company's stock valued at $235,000 after buying an additional 55,867 shares during the last quarter. Public Employees Retirement System of Ohio bought a new stake in shares of CureVac in the 3rd quarter valued at about $91,000. Barclays PLC purchased a new position in shares of CureVac in the 3rd quarter worth approximately $67,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of CureVac by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company's stock worth $162,000 after acquiring an additional 4,425 shares in the last quarter. 17.26% of the stock is currently owned by hedge funds and other institutional investors.
CureVac Company Profile
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
See Also
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
